Relation of atrial remodeling to circulating biomarkers of myocardial fibrosis and apoptotic microparticles in patients with atrial fibrillation and heart failure with preserved ejection fraction

Back

ESC Premium Access

Relation of atrial remodeling to circulating biomarkers of myocardial fibrosis and apoptotic microparticles in patients with atrial fibrillation and heart failure with preserved ejection fraction

Session: Prevention of thromboembolism and atrial remodelling in atrial fibrillation

Topic: Atrial Stressors

Speaker: Associate Professor M. Dzeshka (Grodno, BY)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Associate Professor Mikhail Dzeshka

Grodno State Medical University, Grodno (Belarus)

0 follower

8 more presentations in this session

Equally high detection rates of atrial fibrillation in patients after a TIA and stroke by systematic ECG monitoring with an implanted device: SPIDER-AF study

Speaker: Doctor F. Goss (Munich, DE)

Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience

Speaker: Doctor A. Graffigna (Trento, IT)

Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study

Speaker: Doctor O. Rutherford (Sarpsborg, NO)

Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Access

Abstract

High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment

Speaker: Professor P. Hjemdahl (Stockholm, SE)

Access the full session

Prevention of thromboembolism and atrial remodelling in atrial fibrillation

Speakers: Associate Professor M. Dzeshka, Doctor F. Goss, Doctor A. Graffigna, Doctor O. Rutherford, Doctor A. Nissen Bonde...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Relation of atrial remodeling to circulating biomarkers of myocardial fibrosis and apoptotic microparticles in patients with atrial fibrillation and heart failure with preserved ejection fraction

About the speaker

Associate Professor Mikhail Dzeshka

8 more presentations in this session

Equally high detection rates of atrial fibrillation in patients after a TIA and stroke by systematic ECG monitoring with an implanted device: SPIDER-AF study

Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience

Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study

Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries

High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment

Access the full session

Prevention of thromboembolism and atrial remodelling in atrial fibrillation

About the event

ESC Congress 2019

ESC 365 is supported by